Eur J Clin Pharmacol (2017) 73:1085–1094 DOI 10.1007/s00228-017-2271-x CLINICAL TRIAL Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention 1 1 2 Szymon Olędzki & Zdzisława Kornacewicz-Jach & Krzysztof Safranow & 1 3 4 Radosław Kiedrowicz & Barbara Gawrońska-Szklarz & Maria Jastrzębska & Jarosław Gorący Received: 3 March 2017 /Accepted: 22 May 2017 /Published online: 6 June 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract blood pressure, and platelet count comparing to that of other Background Antiplatelet response to clopidogrel and its influ- patients. LTPR was significantly associated with no history of ence upon the risk of cardiovascular adverse events among hypertension, younger age, lower platelet count, absence of patients with stable coronary artery disease undergoing percu- the CYP2C19*2 variant, and lower CRP plasma level. taneous coronary intervention (PCI) has not been investigated Overall, cardiac adverse events were noted in 14.23% pa- fully. tients. Survival analysis with the Cox proportional hazard Methods Two hundred eleven patients treated with aspirin model showed no influence of residual platelet reactivity dur- and clopidogrel were included in the study. Immediately be- ing clopidogrel therapy upon both ischemic and hemorrhagic fore
European Journal of Clinical Pharmacology – Springer Journals
Published: Jun 6, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud